OR WAIT null SECS
September 15, 2010
The author describes the types and sources of rouge and explains ways to prevent and mitigate this problem.
September 01, 2010
Both biosimilar and generic drugs have an abbreviated approval process; however, the clinical trial requirements differ enormously.
In light of the impressive size and predicted growth of the market, there has been a rising interest in the development of biosimilars.
August 01, 2010
The different pathways to regulatory approval of a biosimilar vary worldwide, ranging from no pathways at all in some developing countries, to the complex and precise mechanism that exists in Europe.
We speak to The European generic Medicines Association about the environment for biosimilars.
As biopharmaceuticals will soon make up 50% of new drug approvals there has been a significant rise in interest in the field of biosimilars.
Why the primary defence against biosimilars is to develop better molecules that can be launched quickly.
June 02, 2010
Editors' picks of pharmaceutical science and technology innovations.
May 19, 2010
PharmTech's monthly newsletter, Equipment and Processing Report, reviews the Editor's Picks for the May 2010 edition from ATMI and SciLog.
March 02, 2010
Analysis of the opportunities and challenges in the biosimilars market.